CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Aurobindo Pharma Ltd (Parent) is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Aurobindo Pharma Ltd (Parent)
Water Mark Building,, Plot No. 11
Survey no.9, Kondapur, Hitech City
Phone: +91 4066725000p:+91 4066725000 HYDERABAD, 500032  India Fax: +91 4023741080f:+91 4023741080
Business Summary
Aurobindo Pharma Limited is an India-based pharmaceutical company. The Company is principally engaged in manufacturing and marketing of active pharmaceutical ingredients, branded pharmaceuticals, generic pharmaceuticals and related services. Its product portfolio is spread over seven therapeutic/product areas encompassing Central nervous systems (CNS), Antiretrovirals (ARVs), Cardiovascular (CVS), SSP - Orals & Sterile, Anti-infectives, Anti-diabetics and Cephalosporins - Orals. It is engaged in developing a range of oncology and hormonal products. It is developing topical as well as transdermal products in the dermatology therapeutic segment. It is also developing about three depot injections based on the microsphere and nano-suspension technology platforms. The Company is marketing its products globally in approximately 150 countries. The Company's subsidiaries include APL Healthcare Limited, Auronext Pharma Private Limited, Auro Peptides Limited, APL Pharma Thai Limited, and others.
(Source: ARS)

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
6/30/20233/31/2023Yes----

Industries
SIC Code Description
2834 Pharmaceutical preparations
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Non-Executive Independent Chairman of the Board KRagunathan 60 6/1/2012 1/30/2008
Executive Vice Chairman of the Board, Managing Director, Promoter K. NityanandaReddy 65 1/1/2022
Chief Financial Officer SanthanamSubramanian 7/1/2014 7/1/2014
6 additional Officers and Directors records available in full report.

Business Names
Business Name
Aurobindo Pharma Limited (Parent)
Aurobindo Pharma USA Inc.
GENERIS Farmacêutica, S.A.
MViyeS Pharma Ventures
Silicon Life Sciences

General Information
Number of Employees: 8,635 (As of 3/31/2012)
Outstanding Shares: 585,938,609 (As of 3/31/2023)
Shareholders: 92,229
Fax Number: +91 4023741080


Copyright © 2023 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Wednesday, September 27, 2023